-- EO-1022 is a potentially differentiated
HER3 ADC designed to address significant unmet needs across
multiple
solid tumors --
-- On-track to file IND application in 2026
--
BOSTON, April 25,
2025 /PRNewswire/ -- Elevation Oncology, Inc.
(Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical needs, today announced new preclinical proof-of-concept
data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The
data will be presented in a late-breaking poster presentation at
the American Association for Cancer Research (AACR) Annual Meeting
2025, being held April 25-30 in
Chicago, Illinois.
"We designed EO-1022 with several notable features, including
glycan site-specific conjugation and MMAE payloads, in order to
address the significant need for a novel HER3 ADC that can
potentially deliver improved efficacy and safety to patients with a
range of solid tumors," said Joseph Ferra, President and Chief
Executive Officer of Elevation Oncology. "Today, we are excited to
share preclinical proof-of-concept data for EO-1022, which indicate
enhanced stability and anti-tumor activity than benchmark HER3 ADCs
in the models tested in vitro and in vivo. We believe
these findings support the potential of EO-1022 in treating
multiple HER3-expressing cancers and look forward to progressing
this program toward the clinic."
EO-1022 is an ADC containing seribantumab, a fully human IgG2
anti-HER3 monoclonal antibody, which is site-specifically
conjugated at glycan to the monomethyl auristatin E (MMAE) payload
with a drug-to-antibody ratio (DAR) of 4. Elevation Oncology
designed EO-1022 leveraging the site-specific ADC technology
platform licensed from Synaffix B.V. Elevation Oncology is
developing EO-1022 for the treatment of solid tumors that express
HER3, including breast cancer and non-small cell lung cancer.
Elevation Oncology expects to file an Investigational New Drug
(IND) application for EO-1022 in 2026.
In a poster titled, "Preclinical discovery and characterization
of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC
for treating solid tumors," Elevation Oncology scientists will
present in vitro and in vivo data that show:
- EO-1022 is highly stable in human serum, with a homogenous DAR
of 4 and minimal free payload compared to seribantumab-vcMMAE and
patritumab-DXd, two benchmark HER3 ADCs, both of which use
stochastic conjugation. These findings illustrate that a key
feature of EO-1022 is minimal systemic exposure to free payload,
potentially resulting in reduced payload-associated toxicity in
patients and an improved safety profile.
- EO-1022 exhibits potent in vitro cytotoxicity that is
dependent on HER3 expression levels.
- EO-1022 elicits anti-tumor activity in in vivo models of
low, medium and high HER3 expression levels, including in a patient
derived xenograft (PDX) model of low HER3-expressing EGFR-mutant
lung cancer.
The poster presentation is now available in the "Publications"
section of Elevation Oncology's website:
https://elevationoncology.com/resources/publications/.
About EO-1022
Elevation Oncology is developing EO-1022, a potentially
differentiated HER3 ADC for the treatment of HER3-expressing solid
tumors, including breast cancer and non-small cell lung cancer.
EO-1022 consists of seribantumab, a fully human IgG2 anti-HER3
antibody, site-specifically conjugated at glycan to the MMAE
payload with a DAR of 4. It leverages seribantumab's desirable
internalization properties and advanced site-specific ADC
technology which makes possible the use of the potent cytotoxic
MMAE payload. Elevation Oncology expects to file an IND application
in 2026.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are leveraging our antibody-drug conjugate
(ADC) expertise to advance EO-1022, a HER3 ADC for the treatment of
patients with HER3-expressing solid tumors. EO-1022 is currently
progressing through preclinical development, with an
investigational new drug (IND) application expected in 2026. For
more information, visit www.ElevationOncology.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated clinical and preclinical development
activities, expected timing of regulatory filings, potential
benefits of product candidates, potential market opportunities for
product candidates and the ability of product candidates to treat
their targeted indications. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These forward-looking statements may be accompanied by
such words as "aim," "anticipate," "believe," "could," "estimate,"
"expect," "forecast," "goal," "intend," "may," "might," "plan,"
"possible," "potential," "will," "would," and other words and terms
of similar meaning. Although Elevation Oncology believes that the
expectations reflected in such forward-looking statements are
reasonable, Elevation Oncology cannot guarantee future events,
results, actions, levels of activity, performance or achievements,
and the timing and results of biotechnology development and
potential regulatory approval are inherently uncertain.
Forward-looking statements are subject to risks and uncertainties
that may cause Elevation Oncology's actual activities or results to
differ significantly from those expressed in any forward-looking
statement, including risks and uncertainties related to Elevation
Oncology's ability to advance its product candidates, the timing
and results of preclinical studies and clinical trials, approvals
and commercialization of product candidates, the receipt and timing
of potential regulatory designations, Elevation Oncology's ability
to fund development activities and achieve development goals,
Elevation Oncology's ability to protect intellectual property,
Elevation Oncology's ability to establish and maintain
collaborations with third parties, and other risks and
uncertainties described under the heading "Risk Factors" in
documents Elevation Oncology files from time to time with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release, and
Elevation Oncology undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Elevation Oncology Investor and Media Contact
Gracie Tong
Senior Director, Investor Relations and Corporate
Communications
gtong@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-presents-preclinical-proof-of-concept-data-for-eo-1022-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025-302437000.html
SOURCE Elevation Oncology